231 related articles for article (PubMed ID: 34048178)
21. Strategic construction of mRNA vaccine derived from conserved and experimentally validated epitopes of avian influenza type A virus: a reverse vaccinology approach.
Herrera-Ong LR
Clin Exp Vaccine Res; 2023 Apr; 12(2):156-171. PubMed ID: 37214143
[TBL] [Abstract][Full Text] [Related]
22. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors.
McCormack E; Adams KJ; Hassan NJ; Kotian A; Lissin NM; Sami M; Mujić M; Osdal T; Gjertsen BT; Baker D; Powlesland AS; Aleksic M; Vuidepot A; Morteau O; Sutton DH; June CH; Kalos M; Ashfield R; Jakobsen BK
Cancer Immunol Immunother; 2013 Apr; 62(4):773-85. PubMed ID: 23263452
[TBL] [Abstract][Full Text] [Related]
23. Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide.
Eikawa S; Kakimi K; Isobe M; Kuzushima K; Luescher I; Ohue Y; Ikeuchi K; Uenaka A; Nishikawa H; Udono H; Oka M; Nakayama E
Int J Cancer; 2013 Jan; 132(2):345-54. PubMed ID: 22729530
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxic T-lymphocyte elicited therapeutic vaccine candidate targeting cancer against MAGE-A11 carcinogenic protein.
Kumar N; Sood D; Gupta A; Jha NK; Jain P; Chandra R
Biosci Rep; 2020 Dec; 40(12):. PubMed ID: 33169789
[TBL] [Abstract][Full Text] [Related]
25. Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting.
Dutoit V; Taub RN; Papadopoulos KP; Talbot S; Keohan ML; Brehm M; Gnjatic S; Harris PE; Bisikirska B; Guillaume P; Cerottini JC; Hesdorffer CS; Old LJ; Valmori D
J Clin Invest; 2002 Dec; 110(12):1813-22. PubMed ID: 12488431
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of cancer/testis antigens expression in patients with non-small cell lung cancer.
Shigematsu Y; Hanagiri T; Shiota H; Kuroda K; Baba T; Mizukami M; So T; Ichiki Y; Yasuda M; So T; Takenoyama M; Yasumoto K
Lung Cancer; 2010 Apr; 68(1):105-10. PubMed ID: 19545928
[TBL] [Abstract][Full Text] [Related]
27. Frequent High Expression of Kita-Kyushu Lung Cancer Antigen-1 (KK-LC-1) in Gastric Cancer.
Shida A; Futawatari N; Fukuyama T; Ichiki Y; Takahashi Y; Nishi Y; Kobayashi N; Yamazaki H; Watanabe M
Anticancer Res; 2015 Jun; 35(6):3575-9. PubMed ID: 26026129
[TBL] [Abstract][Full Text] [Related]
28. Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients.
Ohue Y; Eikawa S; Okazaki N; Mizote Y; Isobe M; Uenaka A; Fukuda M; Old LJ; Oka M; Nakayama E
Int J Cancer; 2012 Sep; 131(5):E649-58. PubMed ID: 22109656
[TBL] [Abstract][Full Text] [Related]
29. Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients' sera using short overlapping peptides and full-length recombinant protein.
Komatsu N; Jackson HM; Chan KF; Oveissi S; Cebon J; Itoh K; Chen W
Mol Immunol; 2013 Jul; 54(3-4):465-71. PubMed ID: 23454162
[TBL] [Abstract][Full Text] [Related]
30. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
31. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors.
Maraskovsky E; Sjölander S; Drane DP; Schnurr M; Le TT; Mateo L; Luft T; Masterman KA; Tai TY; Chen Q; Green S; Sjölander A; Pearse MJ; Lemonnier FA; Chen W; Cebon J; Suhrbier A
Clin Cancer Res; 2004 Apr; 10(8):2879-90. PubMed ID: 15102697
[TBL] [Abstract][Full Text] [Related]
32. Reverse vaccinology approach to design a novel multi-epitope subunit vaccine against avian influenza A (H7N9) virus.
Hasan M; Ghosh PP; Azim KF; Mukta S; Abir RA; Nahar J; Hasan Khan MM
Microb Pathog; 2019 May; 130():19-37. PubMed ID: 30822457
[TBL] [Abstract][Full Text] [Related]
33. Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011.
Karbach J; Pauligk C; Bender A; Gnjatic S; Franzmann K; Wahle C; Jäger D; Knuth A; Old LJ; Jäger E
Int J Cancer; 2006 Feb; 118(3):668-74. PubMed ID: 16152624
[TBL] [Abstract][Full Text] [Related]
34. Designing a multi-epitope vaccine for cross-protection against Shigella spp: An immunoinformatics and structural vaccinology study.
Nosrati M; Hajizade A; Nazarian S; Amani J; Namvar Vansofla A; Tarverdizadeh Y
Mol Immunol; 2019 Dec; 116():106-116. PubMed ID: 31634814
[TBL] [Abstract][Full Text] [Related]
35.
Schmidt J; Guillaume P; Dojcinovic D; Karbach J; Coukos G; Luescher I
J Biol Chem; 2017 Jul; 292(28):11840-11849. PubMed ID: 28536262
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of expression of cancer/testis antigen and down-regulation of HLA class-I in patients with stage I non-small cell lung cancer.
Hanagiri T; Shigematsu Y; Shinohara S; Takenaka M; Oka S; Chikaishi Y; Nagata Y; Baba T; Uramoto H; So T; Yamada S
Anticancer Res; 2013 May; 33(5):2123-8. PubMed ID: 23645764
[TBL] [Abstract][Full Text] [Related]
37. Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1.
Kudela P; Sun Z; Fourcade J; Janjic B; Kirkwood JM; Maillere B; Zarour HM
J Immunol; 2011 Jan; 186(1):312-22. PubMed ID: 21131422
[TBL] [Abstract][Full Text] [Related]
38. A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.
Ebert LM; Liu YC; Clements CS; Robson NC; Jackson HM; Markby JL; Dimopoulos N; Tan BS; Luescher IF; Davis ID; Rossjohn J; Cebon J; Purcell AW; Chen W
Cancer Res; 2009 Feb; 69(3):1046-54. PubMed ID: 19176376
[TBL] [Abstract][Full Text] [Related]
39. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients.
Atanackovic D; Altorki NK; Stockert E; Williamson B; Jungbluth AA; Ritter E; Santiago D; Ferrara CA; Matsuo M; Selvakumar A; Dupont B; Chen YT; Hoffman EW; Ritter G; Old LJ; Gnjatic S
J Immunol; 2004 Mar; 172(5):3289-96. PubMed ID: 14978137
[TBL] [Abstract][Full Text] [Related]
40. Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarker.
Zeng G; Aldridge ME; Wang Y; Pantuck AJ; Wang AY; Liu YX; Han Y; Yuan YH; Robbins PF; Dubinett SM; deKernion JB; Belldegrun AS
Int J Cancer; 2005 Mar; 114(2):268-73. PubMed ID: 15540228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
